Site for LungMAP: A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER
This is a screening study and there is no treatment. The purpose of this study is to collect blood samples to determine if you are able to participate in other LUNGMAP studies.
If you decide to take part in this study, we will ask you to submit a tumor sample which will be tested for specific genes and proteins. Based on the test results, you will be assigned to one of the treatment sub-studies. Even if you do not take part in any of the sub-studies for treatment, your study doctor will check your health status for this study every six months for up to three years. At the follow up visits you will have a physical exam, and scans. Your doctor may give you other tests or procedures if they think they are needed for the regular care of your disease.
at least one line of systemic therapy for any stage of disease
Patients with known EGFR sensitizing mutations, EGFR T790M mutation, ALK gene fusion, ROS 1 gene rearrangement, or BRAF V600E
Patients must have Zubrod performance status 0-1
Patients must be ≥ 18 years of age.
Patients under age of 18
Criteria documentation within 28 days